fashion -WSS

fashion

author：leisure time 2025-10-01 07:41:30 - browse：82798

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why sickle cell disease is getting the first CRISPR treatment

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Americans' trust in science, scientist continues decline: Report

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

BIO selects John Crowley as new CEO

Takeda, Janssen join wearable maker to measure scratching

hotspot

fashion

leisure time

New air purifier tech could be key to improving indoor air quality

Flagship Pioneering launches a new biotech in two countries

Malaria cases in Florida and Texas: Here’s what you need to know

Diagnostic tests are hitting their mathematical limits

At least 13 dead in Texas as scorching temps continue

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

In Memoriam: Notable people who died in 2023

What causes an itch? Researchers may have solved the mystery

Alkermes shareholders re

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

30 years of 'Listening to Prozac'

Pharma patents targeted by Biden in move to slash drug prices

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Cigna, Humana reportedly in talks to merge

FDA needs staff influx to meet gene therapy needs, Marks says

Cigna, Humana reportedly in talks to merge

entertainment

knowledge

Wikipedia

focus